Technical Data Sheet

Purified Mouse Anti-Human IFN-y

Product Information

 Material Number:
 554699

 Size:
 0.1 mg

 Concentration:
 0.5 mg/ml

 Clone:
 B27


 Immunogen:
 Human E.coli-expressed IFN-γ Recombinant Protein


Storage Buffer: Aqueous buffered solution containing ≤0.09% sodium azide.

Description

The B27 antibody reacts with human interferon- γ (IFN- γ). The immunogen used to generate the B27 hybridoma was *E.coli*-expressed recombinant human IFN- γ . This is a neutralizing antibody. The use of B27 antibody for epitope mapping of human IFN- γ has been described. The B27 antibody has been reported not to bind to denatured IFN- γ .

This antibody is routinely tested as a blocking control for intracellular staining. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.





Expression of IFN-y by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (50 ng/ml; Sigma, Cat. No. P-8139) and calcium ionophore A23187 (250 ng/ml; Sigma, Cat. No. C-9275) in the presence of GolgiStop™ (2 µM; Sigma, Cat. No. M-5273). The PBMC were stained with PE-Cy5-anti-CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of PE-mouse anti-human IFN-y antibody (Cat. No. 554701), following the BD Pharmingen™ staining protocol (left panel). To demonstrate specificity of staining, binding by the PE-B27 antibody was blocked by preincubation of fixed/permeabilized cells with excess unlabeled B27 antibody (5 µg; Cat. No. 554699; right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabeled antibody blocking control.

Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4° C.

Application Notes

Application

IC/FCM Block	Routinely Tested
Immunoprecipitation	Reported
Neutralization	Reported

BD Biosciences

bdbiosciences.com

 United States
 Canada
 Europe
 Japan
 Asia Pacific
 Latin America/Caribbean

 877.232.8995
 888.259.0187
 32.53.720.550
 0120.8555.90
 65.6861.0633
 55.11.5185.9995

For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company, ©2006 BD



Recommended Assay Procedure:

Blocking Control for Intracellular Staining: The purified B27 antibody can be used as a blocking control to demonstrate specificity of IFN- γ staining by PE-B27 antibody or FITC-B27 antibody (Cat. No. 554701/554700). To perform this control, the fixed/permeabilized cells (~1 million) can be incubated with 1-10 μg of unlabeled B27 antibody (Cat. No. 554669) for 20 minutes at 4°C, prior to staining with PE-B27 antibody or FITC-B27 antibody (e.g., 0.1-0.5 μg mAb/1 million cells). The intracellular cytokine staining technique and use of blocking controls are described in detail by C. Prussin and D. Metcalfe.

Neutralization: The NA/LETM B27 antibody is useful for neutralization of human IFN- γ bioactivity. This purified B27 antibody (Cat. No. 554698) is supplied in sodium azide free, sterile-filtered (0.22 μm pore) PBS, pH 7.2. Endotoxin level as determined by LAL assay is less than 0.01 ng/μg protein. A suitable NA/LETM mouse IgG1 isotype control to match the NA/LETM B27 antibody is the 107.3 antibody, Cat. No. 554721.

IP/WB: The B27 antibody has been reported to be useful for immunoprecipitation studies. The B27 antibody has been reported not to bind to denatured IFN-γ.

Suggested Companion Products

Catalog Number	Name	Size	Clone	
555061	HiCK-1 Cytokine Positive Control Cells	5x10^6 cells	(none)	
555334	PE-Cy5 Mouse Anti-Human CD3	100 tests	UCHT1	
554701	PE Mouse Anti-Human IFN-γ	0.1 mg	B27	
554698	NA/LE Mouse Anti-Human IFN-γ	0.5 mg	B27	

Product Notices

- 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- 2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

References

Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. *Immunol Rev.* 1992; 127:5-24.(Clone-specific)

Favre C, Wijdenes J, Cabrillat H, Djossou O, Banchereau J, de Vries JE. Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. *Mol Immunol.* 1989; 26(1):17-25.(Clone-specific: Immunoprecipitation, Neutralization, Western blot)

Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. *J Immunol Methods*. 1995; 188(1):117-128.(Methodology: IC/FCM Block)

554699 Rev. 2 Page 2 of 2